August 2015, Volume 1, Issue 8

August 2015

Volume 1, Issue 8

This month, we take a behind-the-scenes look at guideline development, debate the length of anticoagulation for cancer-associated thrombosis, and report on the latest hematologic research from the American Society of Clinical Oncology annual meeting and the International Society on Thrombosis and Haemostasis 2015 Congress.

Table of Contents

August 2015

Equal Under the Law

Saturday, August 1st, 2015
What a remarkable couple of months it has been for the law, and for our patients. On Friday, June 26, the highest court in the...

August 2015

ASH Remembers Deborah Christian, New ACCC President, and more

Saturday, August 1st, 2015
Deborah Christian (1962-2015) Deborah Christian, publications manager at the American Society of Hematology (ASH), passed away on July 6. In her decade of employment at...

ASH Announces This Year’s Top Award Recipients

Saturday, August 1st, 2015
Each year, the Society recognizes outstanding hematologists who have made significant contributions to the field with the following Honorific Awards: Wallace H. Coulter Award...

August 2015

For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?

Saturday, August 1st, 2015
Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen...

How Guidelines Happen

Saturday, August 1st, 2015
Clinical practice guidelines serve as guideposts for providing evidence-based care for patients, assisting clinicians in decision-making. They may focus on providing the best value...

A Life in Music: John F. Tisdale, MD

Saturday, August 1st, 2015
Where did your interest in music start? There are two parts to my musical history: One is that I have spent a lot of time...

August 2015

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Saturday, August 1st, 2015
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are cancers that affect the same lymphocytes, a type of white blood cell. CLL and...

Should ATRA be held in a patient with acute promyelocytic leukemia and a high...

Saturday, August 1st, 2015
This month, Geoffrey L. Uy, MD, answers a question about white blood cell counts in a patient being treated for acute promyelocytic leukemia.A 52-year-old...

August 2015

Double-Drug Combos Equivalent to Triple-Drug Regimens in Multiple Myeloma

Saturday, August 1st, 2015
For patients with transplant-ineligible multiple myeloma (MM), a two-drug combination of bortezomib plus dexamethasone resulted in a similar duration of progression-free survival (PFS) as...

ATG in Cord Blood Transplantation: Is Timing Everything?

Saturday, August 1st, 2015
The practice of using antithymocyte globulin (ATG) to overcome the risks of graft rejection in patients who require allogeneic hematopoietic stem cell transplantation with...
WIB_icon

Rethinking Genetic Profiles in Acute Myeloid Leukemia: It’s All in the CEBPA-Mutated Family

Saturday, August 1st, 2015
Though familial leukemia is rare, its prevalence is likely underestimated due to variations in disease phenotype and latency, as well as a lack of...

Supreme Court Rules on ACA, CMS Updates Medicare Physician Fee Schedule, and more

Saturday, August 1st, 2015
Supreme Court Votes to Uphold Tax Subsidies Under the Affordable Care Act In a 6-3 ruling, the Supreme Court voted to uphold the tax subsidies outlined...

Baseline Patient Characteristics Can Pinpoint Response to Therapy for Multiple Myeloma

Saturday, August 1st, 2015
The initial response to therapy in a patient with newly diagnosed, symptomatic multiple myeloma (MM) can impact long-term treatment response and survival, but it...

APEX, STORM, and more

Saturday, August 1st, 2015
LEUKEMIA Selected by David Steensma, MD A Study of the Safety and Pharmacokinetics of RO6839921, an MDM2 Antagonist, in Patients with Advanced Cancers, including Acute Myeloid...
WIB_icon

A New Treatment Option for Patients with Severe von Willebrand Disease?

Saturday, August 1st, 2015
Treatment options to limit the risk of life-threatening bleeds associated with severe von Willebrand disease (vWD), a condition caused by a deficiency in or...
WIB_icon

Examining Toxicity Profiles for Multiple Myeloma Regimens

Saturday, August 1st, 2015
Though treatment combinations such as melphalan, prednisone, and thalidomide (MPT-T) and melphalan, prednisone, and bortezomib (MPV) have improved survival in patients with multiple myeloma...

Clonal Evolution: In Aplastic Anemia, Which Mutations Matter?

Saturday, August 1st, 2015
Mutations in a specific set of genes may predict whether patients with aplastic anemia develop hematologic malignancies, according to research recently published in The New...

August 2015

Early Trial of Gene Therapy Option for Patients with Hemophilia B

Saturday, August 1st, 2015
Early results from an open-label phase I/II study of a new gene therapy product, named BAX335, offer promise of a long-term alternative to Factor...

CLL-IPI: A New and Improved Staging System for CLL?

Saturday, August 1st, 2015
In a recent study examining the validity of prognostic markers for patients with chronic lymphocytic leukemia (CLL), researchers believe they have developed an internationally...

Study Finds Idarucizumab Can Reverse the Anticoagulant Effects of Dabigatran

Saturday, August 1st, 2015
The experimental drug idarucizumab quickly and effectively reversed the anticoagulant effect of dabigatran within minutes, according to results from an interim analysis presented at...

Pacritinib Leads to Better Symptom Control, Improved Cytopenias in Myelofibrosis

Saturday, August 1st, 2015
Compared with other available treatments, the JAK2 inhibitor pacritinib leads to more effective spleen volume reduction and better symptom control in patients with myelofibrosis,...

For Occult Cancer in VTE Patients, Routine Screening Is Enough

Saturday, August 1st, 2015
For the more than 500,000 Americans and Canadians who are diagnosed with unprovoked venous thromboembolism (VTE) each year, VTE may be an early sign...

Great Strides in Survivorship of Childhood Cancer Since the 1970s

Saturday, August 1st, 2015
More refined treatment and modern screening methods have led to improved long-term survival rates for children and young adults diagnosed with cancer – particularly...

SHARE